Isracann Biosciences' Subsidiary Praesidio Health Submits NPNs To Health Canada
Isracann Biosciences' Subsidiary Praesidio Health Submits NPNs To Health Canada
Isracann board member Dr. George Vrabec, MD FRCSC (Urol.) an experienced principal investigator of numerous clinical trials stated, "Our recent NPN submission to Health Canada moves us closer to credentializing natural health as agents of choice for conditions that may be incompletely treated by conventional pharmaceutical drugs. The application of our NPN's in these, usually chronic conditions including post-viral syndrome, low libido, lower urinary tract symptoms, and generalized anxiety, when validated, may move these into a preferred first line of care in the primary care setting."Praesidio Health, a wholly-owned subsidiary of Isracann Biosciences Inc. (OTCPK:ISCNF) (CSE:IPOT) (XFRA:A2PT0E), has completed the natural product number (NPN) submissions to Health Canada for its first formulations.
全資子公司Praesidio Health的Isracann Biosciences Inc.(OTCPK：ISCNF)(CSE：IPOT)(XFRA：A2PT0E)，已經完成了向加拿大衞生部提交其第一批配方的天然產品編號(NPN)。
Praesidio Health is a Canadian medical research company that develops and validates natural health products ("NHPs") using an evidence-based process has submitted all first-round product formulations to Health Canada for review and approval as natural health products under a class 2 NPN submission. It is anticipated that approvals will be expedited due to the fundamental natural ingredient makeup of the formulations.
Praesidio Health是一家加拿大醫學研究公司使用循證流程開發和驗證天然保健品(“NHP”)的加拿大衞生部已將所有首輪產品配方提交給加拿大衞生部，作為天然保健品的第二類NPN提交審查和批准。由於配方的基本天然成分構成，預計審批將加快。
Isracann board member Dr. George Vrabec, MD FRCSC (Urol.) an experienced principal investigator of numerous clinical trials stated, "Our recent NPN submission to Health Canada moves us closer to credentializing natural health as agents of choice for conditions that may be incompletely treated by conventional pharmaceutical drugs. The application of our NPN's in these, usually chronic conditions including post-viral syndrome, low libido, lower urinary tract symptoms, and generalized anxiety, when validated, may move these into a preferred first line of care in the primary care setting."
以色列董事會成員George Vrabec博士、MD FRCSC(Urol.)一位經驗豐富的多項臨牀試驗的首席調查員説：“我們最近向加拿大衞生部提交的NPN使我們更接近於將自然健康作為常規藥物可能無法完全治療的疾病的首選藥物。我們的NPN在這些通常是慢性疾病中的應用，如病毒後綜合徵、性慾低下、下尿路症狀和廣泛性焦慮，一旦得到驗證，可能會將這些納入初級保健環境的首選一線護理。”
Company management believes that because of the Praesidio acquisition, the outlook for near-term revenue generation is increasingly positive with current strategic goals targeting completion of initial product formulations in readiness for store shelves in both Canada and the USA during Q4 2022.
公司管理層認為，由於對Praesidio的收購，近期創收前景日益樂觀，目前的戰略目標是完成初步產品配方，為2022年第四季度在加拿大和美國的商店上架做好準備。
Company CEO & president Phil Floucault states, "Our proprietary formulations are designed to be unique in the marketplace, utilizing the latest studies in nutraceutical science. In keeping with our DNA to use evidenced-based practices, once the formulations are approved by Health Canada, we plan to test each formulation via third-party consumer studies and advance towards commercialization as quickly as possible. We are also advancing our CMO partnerships in both Canada and the US to ensure our manufacturing and supply chain needs are fulfilled in the near term. We look forward to a fast track to sales in 2022."
公司首席執行官兼總裁菲爾·弗洛科在美國，“我們的專利配方被設計成在市場上是獨一無二的，利用了營養學的最新研究。為了保持我們使用循證實踐的DNA，一旦配方獲得加拿大衞生部的批准，我們計劃通過第三方消費者研究來測試每個配方，並儘快走向商業化。我們還在推進我們在加拿大和美國的CMO合作伙伴關係，以確保我們的製造和供應鏈需求在短期內得到滿足。我們期待着在2022年實現快速銷售。”
Related News
相關新聞
Isracann Biosciences Acquires Praesidio Health And Appoints Natural Health Products Officers
Isracann生物科學公司收購Praesidio Health並任命天然保健品官員
